FTH1 Antibody

What is FTH1 and why is it an important research target?

FTH1 (Ferritin Heavy Chain 1) is a crucial subunit of the ferritin protein complex that plays an essential role in iron metabolism. It exhibits ferroxidase activity, catalyzing the transformation of cytoplasmic Fe2+ into Fe3+, which enables iron storage and reduces the formation of lipid peroxides . This protein is ubiquitously expressed and has a molecular weight of approximately 21 kDa .

FTH1 is a significant research target because:

• It is involved in maintaining intracellular iron homeostasis

• It protects cells against oxidative stress by reducing reactive oxygen species (ROS) production

• Its dysregulation has been implicated in multiple disease states including cancer, osteoarthritis, and neurological disorders

• It serves as a potential biomarker for disease progression and therapeutic target

What are the common applications for FTH1 antibodies in research settings?

Based on research literature, FTH1 antibodies are commonly utilized in several research techniques:

These applications enable researchers to detect, localize, and quantify FTH1 expression across different experimental systems. For reliable results, it's crucial to validate antibody specificity using appropriate positive and negative controls for each application .

How should researchers optimize immunostaining protocols for FTH1 detection?

Optimal FTH1 immunostaining requires careful consideration of several methodological factors:

For IHC applications:

• Heat-mediated antigen retrieval using Tris/EDTA buffer is recommended for optimal epitope exposure

• Blocking with 5% bovine serum albumin for 1 hour at 37°C reduces non-specific binding

• A reaction enhancer may be added to samples and incubated for 20 minutes at 37°C before IHC staining

• For detection, HRP-labeled secondary antibodies (1:1,000 dilution) with diaminobenzidine counterstaining (1:1,000, 5-8 min) provide clear visualization

• Hematoxylin counterstaining (20 seconds) helps identify cellular structures

For immunofluorescence protocols:

• Fixation in 4% paraformaldehyde for 15 minutes at room temperature is recommended

• Permeabilization with 0.1% Triton X-100/Tween-20 facilitates antibody penetration

• For co-localization studies, DAPI can be used for nuclear counterstaining

• Using appropriate excitation wavelengths for the chosen fluorophore (e.g., DyLight 488 maximum emission at 518 nm)

What are the critical steps for successful Western blot analysis of FTH1?

When performing Western blot for FTH1 detection, researchers should consider:

• Sample preparation: Due to FTH1's ubiquitous expression, careful normalization of protein loading is essential for comparative studies.

• Expected molecular weight: The calculated molecular weight of FTH1 is approximately 21 kDa . Bands appearing at this position should be verified with positive controls.

• Antibody dilution optimization: Most commercial FTH1 antibodies work effectively at dilutions of 1:500-1:1,000 for Western blotting .

• Detection sensitivity: Endogenous FTH1 can be detected in various human, mouse, rat, and monkey samples without the need for overexpression .

• Storage conditions: Store antibodies at -20°C for long-term storage or at 4°C for up to one month, avoiding repeated freeze-thaw cycles that may compromise antibody integrity .

How does FTH1 expression correlate with cancer progression?

Research has demonstrated significant correlations between FTH1 expression and cancer progression:

Pancreatic Ductal Adenocarcinoma (PDAC):

• FTH1 expression is weak in normal pancreatic tissues but significantly increased in malignant pancreatic tissues

• High FTH1 expression strongly correlates with advanced TNM stage and poor prognosis

• Approximately 60% of patients with advanced-stage PDAC demonstrate high FTH1 expression

• In the LSL-KrasG12D/Pdx1 (KC) mouse model, FTH1 protein expression increases progressively with disease development, showing significantly higher levels at 6, 9, and 12 months compared to 1-month benchmarks

Head and Neck Squamous Cell Carcinoma (HNSCC):

• FTH1 has been identified as a key therapeutic target and biomarker in HNSCC

• Tanshinone IIA (TanIIA) treatment has been shown to inhibit FTH1 expression in FaDu cells, significantly affecting cell survival and suppressing invasive capacity

These findings suggest that FTH1 may serve as both a prognostic biomarker and potential therapeutic target in multiple cancer types.

What is the relationship between FTH1 and osteoarthritis?

Recent research has established important connections between FTH1 and osteoarthritis (OA) progression:

• Protective role in cartilage maintenance:

  • FTH1 plays an essential role in preventing extracellular matrix degradation, ferroptosis, and chondrocyte senescence during OA progression

  • Knockdown of FTH1 in primary murine chondrocytes results in:

    • Downregulation of cartilage synthesis markers (aggrecan and collagen type II)

    • Marked elevation of chondrocyte senescence indicators (P16 and P21)

    • Decreased SOX9 expression, characteristic of a chondrocyte senescence phenotype

• Mechanistic insights:

  • FTH1 appears to protect against OA by inhibiting the MAPK pathway

  • The protective function likely relates to FTH1's ability to reduce reactive oxygen species (ROS), which are closely linked to chondrocyte senescence

  • FTH1's role in maintaining iron homeostasis helps prevent ferroptosis in chondrocytes, a process that contributes to OA development

These findings suggest potential therapeutic approaches targeting FTH1 pathways for OA treatment.

How can researchers study FTH1's role in ferroptosis regulation?

Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation. To investigate FTH1's role in this process, researchers can employ several approaches:

• Gene manipulation strategies:

  • Utilize lentiviral transduction to establish stable FTH1-knockdown cells (as demonstrated with shFTH1#1, #3, and #4 constructs)

  • Verify knockdown efficiency through Western blotting and qRT-PCR

  • When selecting knockdown clones, carefully assess potential compensatory changes in FTL (Ferritin Light Chain) expression

• Functional assessments:

  • Cell viability assays (e.g., MTT) to measure acute effects of FTH1 manipulation

  • Clonogenic assays for long-term effects on proliferation and survival

  • Flow cytometry to analyze cell cycle distribution changes following FTH1 knockdown

  • ROS detection assays to quantify oxidative stress levels

• Mechanistic investigations:

  • Examine the relationship between FTH1 and ferroptosis markers (GPX4, SLC40A1, TFRC, NFE2L2)

  • Assess lipid peroxidation levels using C11-BODIPY or other fluorescent probes

  • Investigate iron metabolism through iron chelation/supplementation experiments

What are the current challenges in quantifying FTH1 in clinical samples?

Researchers face several technical challenges when quantifying FTH1 in clinical samples:

• Sample preparation considerations:

  • For cerebrospinal fluid (CSF) analysis, commercial enzyme-linked immunosorbent assays have been successfully employed

  • Standard protocols involve combining 20 μl of standards/samples with 100 μl of Enzyme Conjugate Reagent

  • After 45-minute room temperature incubation, plates require thorough washing (5× with distilled water)

  • TMB Reagent (100 μl) should be added and incubated in the dark for 20 minutes before adding Stop Solution

• Assay performance metrics:

  • Standard curves should be linear in the range of anticipated sample values (0-150 ng/mL has been effective for CSF samples)

  • Precision: Intra-assay coefficient of variation (CV) should be below 5% (reported at 4.27% for CSF Fth1)

  • Accuracy: Spike recovery should approach 100% (reported at 98% for CSF Fth1)

• Interpretation challenges:

  • Distinguishing between normal physiological variations and pathological changes

  • Accounting for potential interference from other iron metabolism proteins

  • Correlating FTH1 levels with clinical outcomes and disease progression

How can researchers investigate FTH1 mutations in relation to neurological disorders?

Recent studies have identified FTH1 variants associated with neurodegeneration with brain iron accumulation (NBIA) disorders. Researchers investigating these relationships should consider:

• Genetic analysis approaches:

  • Screen for heterozygous nonsense variants, particularly in the final exon of FTH1

  • Assess whether identified variants escape nonsense-mediated decay (NMD)

  • Consider both germline and de novo mutations in study design

• Cellular model development:

  • Establish primary fibroblast lines from affected individuals and controls

  • Culture cells following standard protocols (e.g., in DMEM with 10% FBS)

  • Passage cells to the third generation to ensure stability

• Protein localization studies:

  • Immunofluorescence assays using cells grown on UV-treated glass coverslips

  • Fixation with 4% paraformaldehyde (15 min at room temperature)

  • Permeabilization with 0.1% Tween 20 in 10% normal goat serum (1 hour)

  • Use dual antibody approach with anti-FTL and anti-FTH primary antibodies

  • Include markers like LAMP1 to assess potential lysosomal association

  • Visualize using appropriate Alexa Fluor secondary antibodies and mount with ProLong Gold Antifade

• Functional assessments:

  • Evaluate markers of oxidative stress

  • Assess iron accumulation patterns

  • Correlate cellular findings with neuroimaging data showing brain iron accumulation

What criteria should researchers use when selecting an FTH1 antibody?

Selecting the appropriate FTH1 antibody is critical for experimental success. Researchers should consider:

• Application compatibility:

  • Confirm the antibody has been validated for your specific application (WB, IHC, ICC, IF)

  • Review validation images provided by manufacturers showing the expected staining patterns

• Species reactivity:

  • Verify reactivity with your species of interest (common reactivities include Human, Mouse, Rat, and Monkey)

  • Consider prediction scores for non-validated species if working with unusual model organisms

• Technical specifications:

  • Antibody host (rabbit is common for FTH1 antibodies)

  • Clonality (polyclonal antibodies provide broader epitope recognition)

  • Isotype (typically IgG)

  • Immunogen information (recombinant protein is common)

• Storage and handling requirements:

  • Optimal storage conditions (-20°C long-term, 4°C for frequent use)

  • Avoid repeated freeze-thaw cycles that may compromise antibody integrity

How should researchers validate FTH1 antibodies for their specific experimental system?

Proper validation ensures reliable and reproducible results when working with FTH1 antibodies:

• Positive and negative controls:

  • Include known positive samples (e.g., liver tissue for FTH1 expression)

  • Use knockout/knockdown samples as negative controls where possible

  • Compare staining patterns with published literature

• Antibody specificity verification:

  • Western blot analysis should show a single band at the expected molecular weight (21 kDa)

  • Immunoprecipitation followed by mass spectrometry can confirm target identity

  • Peptide competition assays using the immunogen peptide

• Optimization for specific applications:

  • Titrate antibody concentrations (start with manufacturer's recommended dilutions)

  • Test multiple fixation protocols for immunostaining applications

  • Optimize blocking conditions to minimize background

• Cross-validation with orthogonal methods:

  • Confirm protein expression using multiple antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression when possible

  • Use complementary detection methods (e.g., both fluorescence and chromogenic detection)

How is FTH1 being investigated as a therapeutic target in disease?

FTH1 is emerging as a promising therapeutic target in several disease contexts:

• Cancer therapy approaches:

  • Natural compounds like Tanshinone IIA (TanIIA) have shown promise in targeting FTH1-mediated processes

  • In FaDu cells (HNSCC), TanIIA treatment inhibits FTH1 expression, affecting cell survival and invasive capacity

  • Knockdown of FTH1 in KRAS-mutant SUIT-2 cells significantly decreases cell viability and colony formation

  • FTH1 knockdown alters cell cycle distribution, reducing G0/G1 phase cells and increasing G2/M phase cells

• Osteoarthritis intervention strategies:

  • Adenovirus-mediated FTH1 expression has been tested in destabilized medial meniscus (DMM) mouse models

  • Protecting FTH1 expression may prevent chondrocyte senescence and extracellular matrix degradation

  • Targeting the FTH1-MAPK pathway interaction appears promising for OA treatment

• Neurological disorder approaches:

  • Understanding how heterozygous nonsense variants in FTH1 lead to neurodegeneration with brain iron accumulation

  • Developing therapies that address the consequences of FTH1 mutations that escape nonsense-mediated decay

  • Potential iron chelation strategies to mitigate the effects of dysregulated iron metabolism

What new methodologies are being developed for studying FTH1 in complex biological systems?

Researchers are developing sophisticated approaches to study FTH1 in complex biological contexts:

• Advanced animal models:

  • LSL-KrasG12D/Pdx1 (KC) mouse models that recapitulate spontaneous PDAC progression in humans show time-dependent increases in FTH1 expression

  • Destabilized medial meniscus (DMM) mouse models for studying FTH1's role in osteoarthritis

  • Models expressing mutant forms of FTH1 to study neurological manifestations

• Multi-omics integration approaches:

  • Combining proteomic analysis of FTH1 expression with transcriptomic data

  • Investigating how FTH1 interacts with ferroptosis markers (GPX4, SLC40A1, TFRC, NFE2L2)

  • Systems biology approaches to understand FTH1's position in iron metabolism networks

• Advanced imaging techniques:

  • Dual immunofluorescence approaches with markers like LAMP1 to assess subcellular localization

  • Correlating cellular FTH1 distribution with neuroimaging findings in NBIA disorders

  • Live-cell imaging to track dynamic changes in FTH1 expression and localization